News | January 24, 2025
Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Reported profit after tax declined 19% year-on-year to Rs 76 crores
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Subscribe To Our Newsletter & Stay Updated
